Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report - Takeaways - MDSpire

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report

  • By

  • Chelsey M. Williams

  • Susanne M. Arnold

  • John L. Villano

  • Erika N. Amarilla Alonso

  • Christine F. Brainson

  • Paul O. Schwarzenberger

  • Sahista Vahora

  • Ayman Qasrawi

  • Reinhold Munker

  • B. Mark Evers

  • Zhonglin Hao

  • July 7, 2026

  • 0 min

Share

  • 1

    The case study reports a 51-year-old female with extensive-stage small-cell lung cancer receiving LB2102 CAR-T therapy off-label.

  • 2

    LB2102 is an investigational CAR-T therapy targeting DLL3, designed to overcome the immunosuppressive tumor microenvironment.

  • 3

    The patient experienced a durable partial response with a 35% reduction in tumor size and stable CNS disease after LB2102 infusion.

  • 4

    No dose-limiting toxicity, cytokine release syndrome, or immune effector cell-associated neurotoxicity occurred post-infusion.

  • 5

    At one year post-treatment, the patient maintained an ECOG performance status of 1 and showed no cancer progression.

Original Source(s)

Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report

  • by Chelsey M. Williams, Susanne M. Arnold, John L. Villano, Erika N. Amarilla Alonso, Christine F. Brainson, Paul O. Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B. Mark Evers, Zhonglin Hao

  • July 7, 2026

Related Content

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
Prostate Cancer Screening—Where We’ve Been, Where We Are, and What Comes Next

Cytokine delivery and targeting strategies in pet dogs with cancer: a comparative immuno-oncology approach